Three Compounds, Three Different Problems
Three Compounds, Three Different Problems
Retatrutide, MOTS-c, GHK-Cu. All three have genuine science behind them — and in all three cases, the research doesn't support what's being claimed, for three entirely different reasons.
Three names circulating right now: retatrutide, MOTS-c, GHK-Cu.
All three have genuine science behind them. Not marketing science — real laboratories, real publications, in one case a full pharmaceutical development programme. Anyone who tells you these are made up is wrong.
And in all three cases, the research that exists does not support what's being claimed about them. For three entirely different reasons.
That's why they're worth walking through together. Not as compound reviews — this piece won't tell you whether to take anything, and it isn't a directory. It's a demonstration of what the series' tools do when you point them at something specific. Each of these three breaks a different assumption, and between them they cover most of the ways the sentence "there's research on it" can be true and useless at the same time.
1. Retatrutide — real evidence, wrong object
Retatrutide is the most legitimate compound in this article and the one most likely to be misunderstood.
It's an investigational drug developed by a major pharmaceutical company, built on the same logic that produced semaglutide and tirzepatide, and pushed a step further. Where semaglutide engages one receptor system and tirzepatide two, retatrutide targets three.
But you can't read that off the name. The -tide ending tells you only that retatrutide is a peptide. There's a tempting pattern among incretin names — -glutide, -dutide, -trutide seem to cluster with one, two, and three receptor targets — but it's pharmacology, not a naming rule: tirzepatide is a dual agonist whose name ends in plain -tide. A stem names the family. It doesn't itemize the targets.
It has been through real clinical trials, with published results, run by people with reputations to lose. The evidence is not the problem.
Here's the gap. Published trial results describe a specific molecule, manufactured to pharmaceutical standard, administered at a defined dose, to screened participants, under monitoring, in a study designed to detect harm as well as benefit.
A vial sold under the same name shares the name. Nothing else about that sentence carries over. There is no relationship between the developer and the seller, no shared supply chain, and no way to establish from the outside that the contents match — which is precisely the Article 1 problem, and precisely what a certificate of analysis exists to address.
So the trial data is real, and it is evidence about something other than the object in front of you.
There's a second issue, quieter and more consequential. Trials generate a dose, and they generate it alongside a titration schedule, an eligibility screen, a monitoring plan and a discontinuation protocol. Extracting the number and discarding the apparatus is how a trial dose becomes an unsafe dose. Article 9 takes that apart in detail.
Status caveat: retatrutide's development is ongoing and its regulatory position may have changed since this was written. Check the date at the foot of this page and verify current status directly.
2. MOTS-c — real biology, thin evidence
MOTS-c has the best origin story in this article, and the story is doing more work than the data.
It's a short peptide — around sixteen amino acids — and what makes it genuinely unusual is where it comes from. Nearly every protein in your body is encoded in the DNA in your cell nucleus. MOTS-c isn't. It's encoded in mitochondrial DNA, the small separate genome inside your mitochondria, a remnant of the ancient bacterium that became the cell's power supply.
That's a real and interesting finding. It suggested a signalling channel running outward from mitochondria to the rest of the cell, which wasn't the established picture, and it opened a category — mitochondrial-derived peptides — that hadn't previously been described.
None of which is evidence that injecting it does anything useful in a person.
The published work on MOTS-c is dominated by cell and animal studies. That's not a criticism of the research — it's the appropriate stage for a recently characterised molecule, and the researchers describe it accurately. The distortion happens downstream, where "shown to improve metabolic function" quietly drops the words in mice.
The pattern to recognize is that mechanistic novelty gets treated as though it were clinical evidence. They're unrelated. A compound can be scientifically fascinating and clinically unestablished at the same time, and the more interesting the mechanism sounds, the more readily the second half gets dropped. An unusual origin is a reason for scientists to investigate something. It is not a reason for anyone to take it.
This is Article 6's tool applied to a compound that isn't a fragment: demonstrated versus asserted. The mitochondrial origin is demonstrated. The human benefit is asserted, and the demonstrated part is being used to make the asserted part feel established.
3. GHK-Cu — real evidence, wrong route
GHK-Cu is the subtlest of the three, because here the evidence is human, published, and in a sense genuinely supportive. It just doesn't support what it's being used to support.
Start with what the thing is. GHK is three amino acids — glycine, histidine, lysine. Three. That's short enough that calling it a peptide is technically correct and practically misleading; it's a small molecule by any working definition, far below the boundaries discussed in Article 4.
The Cu is copper. GHK binds copper ions tightly, and the copper isn't a contaminant or an additive — it's part of the entity. The histidine residue is what grips it, which is the same chemistry noted in the amino acid tables: histidine is the standard biological metal-binder.
The evidence base for GHK-Cu is overwhelmingly topical. It appears in cosmetic formulations, applied to skin, with the outcomes measured being skin outcomes. That's a real, regulated, commercially established use, and it's where the human data lives.
Injected use is a different proposition. Applying a copper complex to the skin surface and introducing it into systemic circulation are not variants of one activity — they differ in how much enters the body, what tissues it reaches, and what has to process it afterwards.
And copper is the part that deserves attention. Copper is an essential trace element under tight homeostatic regulation, and both deficiency and excess cause defined clinical problems. Systemic copper administration is therefore not a neutral background detail of the peptide — it's a separate exposure with its own toxicology, and the topical evidence base says essentially nothing about it, because topical application was never delivering a meaningful systemic copper load in the first place.
So: real evidence, correctly reported, for a use that isn't the one under discussion.
The pattern
Three compounds, three ways "there's research on it" comes apart:
| Compound | The research is real | What it doesn't establish |
|---|---|---|
| Retatrutide | Human trials, major developer | That any of it describes the vial being sold |
| MOTS-c | Genuine, novel biology | That it does anything in a human |
| GHK-Cu | Human, published, positive | That it transfers from skin to injection |
None of these requires believing anyone is lying. In all three cases the underlying science is accurately described. The failure is in the step nobody states out loud — the assumption that evidence about one thing is evidence about this thing.
That step is where almost all of the misleading happens in this market, and it's harder to spot than fabrication, because there's nothing false to catch.
Where this fits
Nothing here is a new tool. Every judgement in this article came from ones the series has already installed: identity (Article 1), naming (Article 2), route (Article 3), demonstrated versus asserted (Article 6), and the protocol questions in Article 9.
That's the point of a worked example. The tools were built on molecules chosen because they teach cleanly. These three were chosen because people are actually buying them — and the tools transfer without modification.
← Back to Article 6: The Fragment Problem → Continue to Article 9: How to Read a Protocol
This article is educational and not medical advice. It does not recommend any compound, dose, protocol, or supplier. Retatrutide is investigational and not approved for human use. MOTS-c and GHK-Cu are not approved as injectable therapeutics; GHK-Cu appears in topical cosmetic products, which is a distinct regulatory category. Decisions about any therapy belong with a qualified clinician who knows your history.
Last verified: 2026-08-10